Table 1.
Key results from cardiovascular outcome trials.
| Trial (Duration) | GLP-1RA | Primary Endpoint | Results |
|---|---|---|---|
| ELIXA (5 years) |
Lixisenatide | CV death, MI, stroke, or hospitalization for UA |
No benefit |
| LEADER (1.5 years) |
Liraglutide | First occurrence of death from CV causes, nonfatal MI, or nonfatal stroke | Significant decrease |
| SUSTAIN-6 (2.1 years) |
Injectable semaglutide | First occurrence of CV death, nonfatal MI, or nonfatal stroke |
Significant decrease |
| PIONEER 6 (15.9 months) |
Oral semaglutide | First occurrence of death from CV causes, nonfatal MI, or nonfatal stroke |
No benefit |
| EXSCEL (7 years) |
Exenatide | First occurrence of death from CV causes, nonfatal MI, or nonfatal stroke | No benefit |
| HARMONY (2.4 years) |
Albiglutide | CV death, nonfatal MI, or stroke |
Significant decrease |
| REWIND (8.4 years) |
Dulaglutide | First occurrence nonfatal MI, nonfatal stroke, or death from CV causes | No benefit |
| AMPLITUDE-O (3 years) |
Efpeglenatide | First MACE: composite of nonfatal MI, nonfatal stroke, or death from CV or undetermined causes | Significant decrease |
CV: cardiovascular; MI: myocardial infarction; UA: unstable angina; MACE: major adverse cardiovascular event.